Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Doctors want to know if giving emapalumab as upfront pre-treatment works well for people with severe acquired aplastic anemia (sAA). This medication is given after diagnosis, but before standard sAA treatment. In people with sAA, stem cells are destroyed and the body cannot make new blood cells.
The purpose of this study is to find the best dose of ABBV-383 to treat AL amyloidosis. The people in this study have AL amyloidosis that came back or does not get better with treatment.
CAR T-cell therapies are a form of immunotherapy where some of a patient's T cells are removed, modified in the laboratory to recognize a protein on cancer cells, multiplied, and returned to the patient to provoke an immune attack against cancer. Sometimes the new T cells cause side effects related to the immune system's response to the treatment.
Researchers want to see how well revumenib works when given with chemotherapy to treat infant leukemia. The children in this study have acute leukemia that came back or keeps growing even after treatment. The leukemia has a gene rearrangement (genetic change) called KMT2A-R.
Researchers want to see how well ivosidenib works to treat conventional chondrosarcoma that has metastasized (spread). Chondrosarcoma is a type of bone cancer that forms in cartilage cells. The people in this study have metastatic conventional chondrosarcoma that has a mutation (change) in the IDH1 gene.
Researchers want to find the best dose of lorlatinib to give with ramucirumab in people with lung cancer. They are also seeing how well this drug combination works. The people in this study have non-small cell lung cancer (NSCLC) that has metastasized (spread). In addition, their cancers have a fusion involving the ALK gene. A fusion gene is made when parts of two different genes in your body join together.
Researchers want to find the best dose of elranatamab when given with carfilzomib and dexamethasone or PF-07901801 in people with multiple myeloma. The people in this study have multiple myeloma that keeps growing or came back after treatment.
In this study, researchers are assessing the safety of the drug lurbinectedin in young people with solid tumors. In the first part, they will find the highest dose of lurbinectedin to use safely in children with solid tumors. If your child joins, this is the part of the study they will be in.
